Isabel Anez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Isabel Anez has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Alison Schwartz Levine
Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA 02215, USA
27 shared publications - Anne Naumer
Huntsman Cancer Institute 7 Primary Children's Hospital, Salt Lake City, Utah
27 shared publications - Judy Ellen Garber
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
27 shared publications - Kara Noelle Maxwell
Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
27 shared publications - Luke D. Maese
University of Utah, Huntsman Cancer Institute, and Primary Children's Hospital, Salt Lake City, UT
27 shared publications - Sophie R. Cahill
Dana-Farber Cancer Institute 5 , Harvard Medical School, Boston, Massachusetts
27 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Variation at the R181 Residue of p53 Confers Loss of p53 DNA Binding Cooperativity with the Retention of Mitochondria-Associated Apoptosis
Figure S1. TP53 c.542G>A;p.R181H and TP53 c.541C>T;p.R181C variants are the most common variants observed at Penn, DFCI, and HCI and confer the risk of various tumors.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Variation at the R181 Residue of p53 Confers Loss of p53 DNA Binding Cooperativity with the Retention of Mitochondria-Associated Apoptosis
Figure S1. TP53 c.542G>A;p.R181H and TP53 c.541C>T;p.R181C variants are the most common variants observed at Penn, DFCI, and HCI and confer the risk of various tumors.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from Variation at the R181 Residue of p53 Confers Loss of p53 DNA Binding Cooperativity with the Retention of Mitochondria-Associated Apoptosis
Figure S10. R181-mutant p53 goes to the mitochondria and induces cytochrome c upon genotoxic stress.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from Variation at the R181 Residue of p53 Confers Loss of p53 DNA Binding Cooperativity with the Retention of Mitochondria-Associated Apoptosis
Figure S10. R181-mutant p53 goes to the mitochondria and induces cytochrome c upon genotoxic stress.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Data from Variation at the R181 Residue of p53 Confers Loss of p53 DNA Binding Cooperativity with the Retention of Mitochondria-Associated Apoptosis
The p53 tumor suppressor binds DNA cooperatively as a tetramer, mediated by salt-bridge interactions between p53 residues E180 and R181 from 2 different p53 monomers. Variants at the R181 residue are one of the most identified TP53 pathogenic variants by germline genetic testing. We show that families with TP53 p.R181H and p.R181C variants have an attenuated cancer risk phenotype compared with patients with hotspot dominant-negative loss-of-function TP53 variants. Despite this phenotype, we find that p53 R181H and R181C variants have significantly reduced ability to bind to p53 promoter/enhancer target sequences and transactivate p53 target genes, similar to null variants. However, p53 R181H and R181C retain wild-type (WT) p53 structure and tetramerization. In addition, R181-mutant cells undergo apoptosis through WT p53 activity at the mitochondria. These results suggest that retention of transcription-independent p53 tumor suppressor function results in a reduced penetrance cancer risk syndrome in humans. Implications:We report the first separation of function DNA-binding domain p53 mutation that results in retention of transcription-independent p53 functions despite loss of p53 transactivation activity, resulting in a reduced penetrance phenotype.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Variation at the R181 Residue of p53 Confers Loss of p53 DNA Binding Cooperativity with the Retention of Mitochondria-Associated Apoptosis
The p53 tumor suppressor binds DNA cooperatively as a tetramer, mediated by salt-bridge interactions between p53 residues E180 and R181 from 2 different p53 monomers. Variants at the R181 residue are one of the most identified TP53 pathogenic variants by germline genetic testing. We show that families with TP53 p.R181H and p.R181C variants have an attenuated cancer risk phenotype compared with patients with hotspot dominant-negative loss-of-function TP53 variants. Despite this phenotype, we find that p53 R181H and R181C variants have significantly reduced ability to bind to p53 promoter/enhancer target sequences and transactivate p53 target genes, similar to null variants. However, p53 R181H and R181C retain wild-type (WT) p53 structure and tetramerization. In addition, R181-mutant cells undergo apoptosis through WT p53 activity at the mitochondria. These results suggest that retention of transcription-independent p53 tumor suppressor function results in a reduced penetrance cancer risk syndrome in humans. Implications:We report the first separation of function DNA-binding domain p53 mutation that results in retention of transcription-independent p53 functions despite loss of p53 transactivation activity, resulting in a reduced penetrance phenotype.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Variation at the R181 Residue of p53 Confers Loss of p53 DNA Binding Cooperativity with the Retention of Mitochondria-Associated Apoptosis
Figure S2. Representative Pedigrees of families with the TP53 p.R181H pathogenic germline variant from Penn Medicine (Penn), Dana-Farber Cancer Institute (DFCI), and Huntsman Cancer Institute (HCI). Probands are indicated by the black arrowhead; slashes indicated deceased status.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Variation at the R181 Residue of p53 Confers Loss of p53 DNA Binding Cooperativity with the Retention of Mitochondria-Associated Apoptosis
Figure S2. Representative Pedigrees of families with the TP53 p.R181H pathogenic germline variant from Penn Medicine (Penn), Dana-Farber Cancer Institute (DFCI), and Huntsman Cancer Institute (HCI). Probands are indicated by the black arrowhead; slashes indicated deceased status.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Variation at the R181 Residue of p53 Confers Loss of p53 DNA Binding Cooperativity with the Retention of Mitochondria-Associated Apoptosis
Figure S5. RNA-sequencing and quantitative PCR of R181-mutant cell lines confirm reduced induction of p53 target genes.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Variation at the R181 Residue of p53 Confers Loss of p53 DNA Binding Cooperativity with the Retention of Mitochondria-Associated Apoptosis
Figure S5. RNA-sequencing and quantitative PCR of R181-mutant cell lines confirm reduced induction of p53 target genes.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Variation at the R181 Residue of p53 Confers Loss of p53 DNA Binding Cooperativity with the Retention of Mitochondria-Associated Apoptosis
Figure S6. Second replicate of ChIP-sequencing and HOMER motif analysis showing retained binding of R181-mutants to ETS sites.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Variation at the R181 Residue of p53 Confers Loss of p53 DNA Binding Cooperativity with the Retention of Mitochondria-Associated Apoptosis
Figure S6. Second replicate of ChIP-sequencing and HOMER motif analysis showing retained binding of R181-mutants to ETS sites.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Variation at the R181 Residue of p53 Confers Loss of p53 DNA Binding Cooperativity with the Retention of Mitochondria-Associated Apoptosis
Figure S7. R181-mutant HCT116 tumors grow similar to WT tumors.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Variation at the R181 Residue of p53 Confers Loss of p53 DNA Binding Cooperativity with the Retention of Mitochondria-Associated Apoptosis
Figure S7. R181-mutant HCT116 tumors grow similar to WT tumors.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Variation at the R181 Residue of p53 Confers Loss of p53 DNA Binding Cooperativity with the Retention of Mitochondria-Associated Apoptosis
Figure S8. R181H and R181C undergo apoptosis upon genotoxic stress.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Variation at the R181 Residue of p53 Confers Loss of p53 DNA Binding Cooperativity with the Retention of Mitochondria-Associated Apoptosis
Figure S8. R181H and R181C undergo apoptosis upon genotoxic stress.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Variation at the R181 Residue of p53 Confers Loss of p53 DNA Binding Cooperativity with the Retention of Mitochondria-Associated Apoptosis
Figure S4. Tetramerization assay with monomeric mutant G334R confirm WT-like retained tetramerization by R181H and R181C.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Variation at the R181 Residue of p53 Confers Loss of p53 DNA Binding Cooperativity with the Retention of Mitochondria-Associated Apoptosis
Figure S4. Tetramerization assay with monomeric mutant G334R confirm WT-like retained tetramerization by R181H and R181C.